Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2015-05-11 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 11, 2015, by Galectin Therapeutics Inc. It specifically mentions that the report is furnished pursuant to Item 7.01 Regulation FD Disclosure and that it includes a corporate presentation attached as Exhibit 99.1. The text states that the presentation was posted on the company's website and is summarized in the report. The document is relatively short (2820 characters) and primarily serves to announce the posting of a corporate presentation rather than containing the full presentation or detailed financial data itself. According to the 'Menu vs Meal' rule, such a short document announcing the availability of a presentation should be classified as a Regulatory Filing (RNS) rather than an Investor Presentation (IP) or other report type. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2015, by Galectin Therapeutics Inc. It announces the results of operations and financial condition for the quarter ended March 31, 2015, referencing a press release attached as Exhibit 99.1. The text explicitly states that the information is being furnished under Item 2.02 of Form 8-K, which pertains to Results of Operations and Financial Condition. The document is relatively short (3768 characters) and primarily serves as an announcement of financial results rather than a full financial report. It includes a press release summary but does not contain detailed financial statements or substantive financial data itself. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2015-05-11 English
10-Q
Interim / Quarterly Report Q1 2015
2015-05-11 English
DEF 14A
Proxy Solicitation & Information Statement
2015-04-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 18, 2015, by Galectin Therapeutics Inc. It specifically references Item 2.02 "Results of Operations and Financial Condition" and attaches a press release announcing the company's financial results for the year ended December 31, 2014. The text states that the information is being furnished, not filed, and incorporates by reference the press release. The document is short (3771 characters) and primarily serves as an announcement of the earnings results via a press release rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains the actual press release text as an exhibit. Therefore, the best classification is Earnings Release (ER).
2015-03-18 English
FORM 10-K
Annual Report FY 2014
2015-03-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.